NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced Tuesday that its independent directors approved an equity award to a new employee under the company’s 2021 Inducement Plan. The grant, effective June 24, 2026, serves as a material inducement for the individual to join the company, as permitted under Nasdaq Listing Rule 5635(c)(4). This rule mandates public disclosure of equity awards not made under a stockholder-approved plan.
The new hire, who was not a previous employee or director of NeuroOne, received an option to purchase 10,000 shares of common stock at an exercise price of $3.27 per share—the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder in 12 equal quarterly installments thereafter. Vesting is contingent on continued employment, with acceleration or forfeiture provisions as outlined in the option agreement.
NeuroOne, based in Eden Prairie, Minnesota, specializes in medical technology for neurological disorders. Its FDA-cleared product families include Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by combining diagnostic and therapeutic functions. The company is also advancing research in drug delivery, basivertebral nerve ablation, and spinal cord stimulation.
This inducement grant underscores NeuroOne's strategy to attract key talent as it expands its pipeline and commercial footprint. For more details, visit nmtc1.com.
